Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Operating Expenses (2016 - 2025)

Protalix BioTherapeutics has reported Operating Expenses over the past 16 years, most recently at $2.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $2.6 million for Q4 2025, up 38.57% from a year ago — trailing twelve months through Dec 2025 was $21.2 million (down 7.29% YoY), and the annual figure for FY2025 was $21.0 million, up 18.38%.
  • Operating Expenses for Q4 2025 was $2.6 million at Protalix BioTherapeutics, down from $7.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for PLX hit a ceiling of $11.9 million in Q1 2022 and a floor of $1.9 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $8.1 million (2023), compared with a mean of $8.0 million.
  • Biggest five-year swings in Operating Expenses: tumbled 73.8% in 2024 and later skyrocketed 38.57% in 2025.
  • Protalix BioTherapeutics' Operating Expenses stood at $11.1 million in 2021, then fell by 21.54% to $8.7 million in 2022, then dropped by 16.87% to $7.2 million in 2023, then tumbled by 73.8% to $1.9 million in 2024, then soared by 38.57% to $2.6 million in 2025.
  • The last three reported values for Operating Expenses were $2.6 million (Q4 2025), $7.8 million (Q3 2025), and $4.7 million (Q2 2025) per Business Quant data.